Synthesis, molecular docking, acetylcholinesterase and butyrylcholinesterase inhibitory potential of thiazole analogs as new inhibitors for Alzheimer disease

Bioorganic Chemistry
Fazal RahimKhalid M Khan

Abstract

A series of thirty (30) thiazole analogs were prepared, characterized by (1)H NMR, (13)C NMR and EI-MS and evaluated for Acetylcholinesterase and butyrylcholinesterase inhibitory potential. All analogs exhibited varied butyrylcholinesterase inhibitory activity with IC50 value ranging between 1.59±0.01 and 389.25±1.75μM when compared with the standard eserine (IC50, 0.85±0.0001μM). Analogs 15, 7, 12, 9, 14, 1, 30 with IC50 values 1.59±0.01, 1.77±0.01, 6.21±0.01, 7.56±0.01, 8.46±0.01, 14.81±0.32 and 16.54±0.21μM respectively showed excellent inhibitory potential. Seven analogs 15, 20, 19, 24, 28, 30 and 25 exhibited good acetylcholinesterase inhibitory potential with IC50 values 21.3±0.50, 35.3±0.64, 36.6±0.70, 44.81±0.81, 46.36±0.84, 48.2±0.06 and 48.72±0.91μM respectively. All other analogs also exhibited well to moderate enzyme inhibition. The binding mode of these compounds was confirmed through molecular docking.

References

Oct 1, 1987·Journal of Clinical Pharmacology·E O Magarian, A J Dietz
Dec 11, 1999·Nucleic Acids Research·H M BermanP E Bourne
Aug 24, 2000·Journal of Agricultural and Food Chemistry·F E DayanJ K Zjawiony
Dec 18, 2001·Journal of Agricultural and Food Chemistry·V T PardíoK N Waliszewski
Apr 6, 2002·Stroke; a Journal of Cerebral Circulation·J C de la Torre
Sep 7, 2002·Stroke; a Journal of Cerebral Circulation·Donald R Royall
Feb 4, 2003·Nature Reviews. Neuroscience·Sultan DarveshChangiz Geula
Apr 5, 2003·Neurochemical Research·Ezio Giacobini
Jul 19, 2003·The Journal of Biological Chemistry·Yvain NicoletFlorian Nachon
Jan 1, 1954·The British Journal of Nutrition·W T BERRYD R DAVIES
Jul 1, 1961·Biochemical Pharmacology·G L ELLMANR M FEATHER-STONE
Nov 9, 2005·Proceedings of the National Academy of Sciences of the United States of America·Nigel H GreigDebomoy K Lahiri
Sep 30, 2006·Bioorganic & Medicinal Chemistry·Wei Huang, Guang-Fu Yang
Jan 18, 2007·Expert Opinion on Therapeutic Targets·Ulrike HolzgrabeEva Kugelmann
Jan 10, 2008·Journal of Medicinal Chemistry·Andrea CavalliCarlo Melchiorre
Mar 9, 2010·Chemico-biological Interactions·Victor P Whittaker
May 3, 2011·Chemical & Pharmaceutical Bulletin·Mohammad Sayed AlamDong-Ung Lee
Feb 4, 2012·Journal of Enzyme Inhibition and Medicinal Chemistry·Gülhan Turan-ZitouniGülşen Akalın Çiftçi
Jul 16, 2013·European Journal of Medicinal Chemistry·Lorena BlauChung Man Chin
May 23, 2014·European Journal of Medicinal Chemistry·Khalid Mohammed KhanM Iqbal Choudhary
Jul 30, 2014·European Journal of Medicinal Chemistry·Muhammad TahaKhalid M Khan
Aug 8, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Syahrul ImranSaima Tauseef
Jun 17, 2015·Bioorganic & Medicinal Chemistry Letters·Muhammad TahaKhalid Mohammed Khan
Jun 20, 2015·Bioorganic & Medicinal Chemistry·Iskandar AbdullahNoorsaadah Abd Rahman
Jul 18, 2015·Bioorganic & Medicinal Chemistry·Muhammad TahaKhalid Mohammed Khan
May 1, 1999·Journal of Computational Chemistry·Thomas A Halgren

❮ Previous
Next ❯

Citations

Nov 30, 2019·Bulletin of Experimental Biology and Medicine·N K KlichkhanovM M Dzharaeva
Oct 28, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Muhammad TahaFarzana Naz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.